Argos Therapeutics Inc. (ARGS) Shares Down 7%
Argos Therapeutics Inc. (NASDAQ:ARGS)’s share price fell 7% on Monday . The company traded as low as $6.20 and last traded at $6.34, with a volume of 110,419 shares changing hands. The stock had previously closed at $6.82.
A number of brokerages recently weighed in on ARGS. Needham & Company LLC reissued a “buy” rating on shares of Argos Therapeutics in a report on Saturday, April 23rd. FBR & Co reissued a “buy” rating on shares of Argos Therapeutics in a report on Saturday, May 14th. Zacks Investment Research raised Argos Therapeutics from a “hold” rating to a “buy” rating and set a $6.75 price objective on the stock in a report on Tuesday, May 17th. Roth Capital raised their price objective on Argos Therapeutics from $11.00 to $18.00 and gave the company a “buy” rating in a report on Tuesday, April 19th. Finally, Stifel Nicolaus decreased their price objective on Argos Therapeutics from $16.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday, March 30th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $11.84.
The firm’s market cap is $165.44 million. The firm has a 50 day moving average price of $6.16 and a 200 day moving average price of $5.61.
Argos Therapeutics (NASDAQ:ARGS) last released its quarterly earnings data on Thursday, May 12th. The biopharmaceutical company reported ($0.57) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.56) by $0.01. Equities research analysts anticipate that Argos Therapeutics Inc. will post ($1.74) earnings per share for the current year.
Argos Therapeutics, Inc (Argos) is a biopharmaceutical company focused on the development and commercialization of personalized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s advanced product candidate is AGS-003, which the Company is developing for the treatment of metastatic renal cell carcinoma (mRCC) and other cancers.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.